[go: up one dir, main page]

WO2019070698A1 - Nouvelles formes d'ibrutinib - Google Patents

Nouvelles formes d'ibrutinib Download PDF

Info

Publication number
WO2019070698A1
WO2019070698A1 PCT/US2018/053954 US2018053954W WO2019070698A1 WO 2019070698 A1 WO2019070698 A1 WO 2019070698A1 US 2018053954 W US2018053954 W US 2018053954W WO 2019070698 A1 WO2019070698 A1 WO 2019070698A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibrutinib
amorphous
pyridine
solvent
pyridine solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/053954
Other languages
English (en)
Inventor
Ronald Mueller
Steven Collier
Padmini KUVURU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson Matthey PLC
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Publication of WO2019070698A1 publication Critical patent/WO2019070698A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present disclosure is related to forms of ibrutinib, i.e., Form H pyridine solvate of ibrutinib Form H, Form I pyridine solvate of ibrutinib and an amorphous form of ibrutinib.
  • the present disclosure also relates to a pharmaceutical composition comprising the forms, their method of use for treating a disease in a patient, and process for the preparation of the forms.
  • Ibrutinib having the chemical designation l-[(3R)-3-[4-Amino-3-(4- phenoxyphenyl)- lH-pyrazolo[3 ,4-d]pyrimidin- 1 -yljpiperidin- 1 -yl]prop-2-en- 1 -one, is an orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
  • BTK Bruton's tyrosine kinase
  • Ibrutinib is commercially marketed under the name EVIBRUVICA® and is indicated for the treatment of patients with mantel cell lymphoma who have received at least one prior therapy.
  • IMBRUVICA® is also indicated for the treatment of patients with chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia.
  • WO2016/207172 amorphous
  • WO2017/029586 Forms S1-S4, and amorphous form
  • WO2017/085628 amorphous form
  • WO2017/137446 amorphous form
  • EP3243824 Forms ⁇ , ⁇ , ⁇ , ⁇ , ⁇ and ⁇ ) and Chinese Publication Nos. CN103121999, and CN 103923084 (II- VIII).
  • ibrutinib and salts thereof gives rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors.
  • Polymorphic forms of the compound are important in that the forms having desirable characteristics, such as ease of handling, ease of processing, ease of formulating, storage stability, ease of purification, improved dissolution or bioavailability, or form that facilitates conversion to another desirable polymorphic form.
  • new polymorphic forms of ibrutinib are useful for providing the compound having desirable characteristics. For at least these reasons, there is a need for additional polymorphic forms of ibrutinib.
  • Amorphous compounds are considered solid state forms of polymorphs, which are chemically identical to other polymorphs but have different physical properties such as crystal lattice energies, melting points, intrinsic solubilities, rates of dissolution, densities, mechanical properties, chemical and physical stability, hygroscopicity, and morphology. The differences in intrinsic solubilities also may lead to differences in the rate of absorption, thus impacting bioavailability.
  • Amorphous ibrutinib is moisture stable. It is therefore a good alternative to crystalline ibrutinib as amorphous material has a higher solubility, which is connected with better bioavailability, than corresponding crystalline forms. For at least these reasons, there is also a need for processes to prepare amorphous ibrutinib.
  • the present invention is directed to novel crystalline forms of ibrutinib, designated herein as Form H pyridine solvate of ibrutinib and Form I pyridine solvate of ibrutinib.
  • the present invention is further directed to processes for the preparation of Form H pyridine solvate of ibrutinib or Form I pyridine solvate of ibrutinib.
  • the present invention also is directed to pharmaceutical compositions comprising Form H pyridine solvate of ibrutinib or Form I pyridine solvate of ibrutinib, and a method for treating disease in a patient using Form H pyridine solvate of ibrutinib or Form I pyridine solvate of ibrutinib.
  • the present invention is also directed to processes for the preparation of amorphous forms of ibrutinib.
  • the present invention also is directed to pharmaceutical compositions comprising crystalline and amorphous ibrutinib, and a method for treating disease using amorphous ibrutinib.
  • FIG. 1 provides a representative X-ray Powder Diffraction ("XRPD") pattern of Form H pyridine solvate of ibrutinib, expressed in terms of °2 ⁇ .
  • XRPD X-ray Powder Diffraction
  • FIG. 2 provides a representative Differential Scanning Calorimetry ("DSC”) and Thermal Gravimetric Analysis (“TGA”) plot of Form H pyridine solvate of ibrutinib.
  • DSC Differential Scanning Calorimetry
  • TGA Thermal Gravimetric Analysis
  • FIG. 3 provides a representative XRPD pattern of amorphous ibrutinib prepared using tetraglyme, expressed in terms of °2 ⁇ .
  • FIG. 4 provides a representative DSC plot of amorphous ibrutinib prepared using tetraglyme.
  • FIG. 5 provides a representative 1 H-NMR plot of amorphous ibrutinib prepared using tetraglyme.
  • FIG. 6 provides a representative XRPD pattern of amorphous ibrutinib prepared using PEG-200, expressed in terms of °2 ⁇ .
  • FIG. 7 provides a representative DSC plot of amorphous ibrutinib prepared using PEG-200.
  • FIG. 8 provides a representative 1 H-NMR plot of amorphous ibrutinib prepared using PEG-200.
  • FIG. 9 provides a representative XRPD pattern of amorphous ibrutinib prepared using pyridine, expressed in terms of °2 ⁇ .
  • FIG. 10 provides a representative DSC plot of amorphous ibrutinib prepared using pyridine.
  • FIG. 11 provides a representative TGA plot of amorphous ibrutinib prepared using pyridine.
  • FIG. 12 provides a representative 1H- MR plot of amorphous ibrutinib prepared using pyridine.
  • FIG. 13 provides a representative X-ray Powder Diffraction ("XRPD") pattern of Form I of ibrutinib, expressed in terms of °2 ⁇ .
  • XRPD X-ray Powder Diffraction
  • FIG. 14 represents the asymmetric unit of Form I pyridine solvate of ibrutinib.
  • FIG. 15 shows the inter and intra molecular hydrogen bonding between ibrutinib and pyridine in Form I pyridine solvate of ibrutinib.
  • the present disclosure is directed to novel crystalline forms of ibrutinib, designated herein as Form H pyridine solvate of ibrutinib and Form I pyridine solvate of ibrutinib, pharmaceutical compositions comprising the forms, process for their preparation, and their use for treating a patient with a physiological condition in need of treatment, as herein described in detail.
  • the present disclosure is also directed processes for the preparation of an amorphous form of ibrutinib, pharmaceutical compositions comprising the form, and its use for treating a patient with a physiological condition in need of treatment, as herein described in detail.
  • a numeric value or a range of values which is provided to characterize a particular solid form e.g., a specific temperature or temperature range, such as, e.g., that describing a DSC or TGA thermal event, including, e.g., melting, dehydration, desolvation or glass transition events, a mass change, such as, e.g., a mass change as a function of temperature or humidity, a solvent or water content, in terms of, e.g., mass or a percentage, or a peak position, such as, e.g., in analysis by IR or Raman spectroscopy or XRPD, indicate that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the particular solid form.
  • a specific temperature or temperature range such as, e.g., that describing a DSC or TGA thermal event, including, e.g., melting, dehydration, desolvation or glass transition events
  • the term “pharmaceutical composition” is intended to encompass the a pharmaceutically effective amount of the amorphous ibrutinib and pharmaceutically acceptable excipient.
  • pharmaceutical compositions includes pharmaceutical compositions such as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.
  • crystalline and related terms used herein, when used to describe a compound, substance, modification, material, component or product, unless otherwise specified, mean that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. See, e.g., Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Baltimore, Md. (2005), The United States Pharmacopeia, 23rd ed., 1843-1844 (1995).
  • excipient refers to a pharmaceutically acceptable organic or inorganic carrier substance. Excipients may be natural or synthetic substances formulated alongside the active ingredient of a medication, included for the purpose of bulking-up formulations that contain potent active ingredients (thus often referred to as “bulking agents,” “fillers,” or “diluents”), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption or solubility. Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance, such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation over the expected shelf life.
  • the term "patient” refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. Preferably, the patient has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented. Further, a patient may not have exhibited any symptoms of the disorder, disease or condition to be treated and/prevented, but has been deemed by a physician, clinician or other medical professional to be at risk for developing said disorder, disease or condition.
  • polymorphic form or related term herein, refer to a crystal form of a molecule, or salt thereof that can exist in two or more forms, as a result different arrangements or conformations of the molecule or salt thereof ions in the crystal lattice of the polymorph.
  • the terms “treat,” “treating” and “treatment” refer to the eradication or amelioration of a disease or disorder, or of one or more symptoms associated with the disease or disorder. In certain embodiments, the terms refer to minimizing the spread or worsening of the disease or disorder resulting from the administration of one or more therapeutic agents to a patient with such a disease or disorder. In some embodiments, the terms refer to the administration of a compound provided herein, with or without other additional active agents, after the onset of symptoms of the particular disease. Ibrutinib is indicated for the treatment of patients with mantel cell lymphoma who have received at least one prior therapy. Ibrutinib is also indicated for the treatment of patients with chronic lymphocytic leukemia and
  • IMBRUVICA® Waldenstrom's macroglobulinemia.
  • IMBRUVICA® is available as 140 mg capsules.
  • the recommended dose of IMBRUVICA® for mantle cell lymphoma is 560 mg (four 140 mg capsules), orally, once daily.
  • lymphocytic leukemia and Waldenstrom's macroglobulinemia is 420 mg (three 140 mg capsules), orally, once daily.
  • One embodiment of the invention is directed to a process for preparing an amorphous form of ibrutinib, comprising producing amorphous ibrutinib from a solvent - anti- solvent system.
  • a further embodiment is wherein the production of the amorphous ibrutinib further comprises recovering the amorphous ibrutinib.
  • a further embodiment is wherein the recovering of the amorphous ibrutinib further comprises drying the amorphous ibrutinib, optionally under vacuum.
  • Another embodiment of the invention is wherein the drying occurs under heated conditions.
  • Another embodiment of the invention is wherein the drying occurs at about at least 35 °C.
  • Another embodiment of the invention is wherein in the production of the amorphous ibrutinib the solvent is selected from the group consisting of tetraglymes, polyethylene glycols, oligomeric ethylene glycols, oligomeric ethylene glycol monomethyl ethers, polyethylene glycol monomethyl ethers and pyridines.
  • polyethylene glycol is selected from the group comprising PEG- 200, PEG-400 and PEG-600, or a combination thereof.
  • Another embodiment of the invention is wherein in the production of the amorphous ibrutinib the anti-solvent is a protic anti-solvent comprising water.
  • Another embodiment of the invention is an amorphous form of ibrutinib, characterized by a T g of about 55 °C.
  • Another embodiment of the invention is an amorphous form of ibrutinib, prepared by the steps of:
  • Another embodiment of the invention is a pharmaceutical composition comprising a pharmaceutically effective amount of an amorphous form of ibrutinib, prepared by the steps of:
  • Another embodiment of the invention is a method of treating disease in a patient comprising administering a pharmaceutical formulation comprising a pharmaceutically effective amount of an amorphous form of ibrutinib, prepared by the steps of:
  • Another embodiment of the invention is wherein the disease is chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom's
  • macroglobulinemia mantle cell lymphoma, marginal zone lymphoma, or chronic graft versus host disease.
  • Another embodiment of the invention is crystalline Form H pyridine solvate of ibrutinib.
  • Another embodiment of the invention is crystalline Form I pyridine solvate of ibrutinib.
  • Another embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically effective amount of crystalline ibrutinib Form H pyridine solvate of ibrutinib or Form I pyridine solvate of ibrutinib and pharmaceutically acceptable excipient.
  • Another embodiment of the invention is a method of treating disease in a patient comprising administering a pharmaceutical formulation comprising a pharmaceutically effective amount of Form H pyridine solvate of ibrutinib or Form I pyridine solvate of ibrutinib and pharmaceutically acceptable excipient to a patient in need thereof.
  • Another embodiment of the invention is wherein the disease is chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom's
  • macroglobulinemia mantle cell lymphoma, marginal zone lymphoma, or chronic graft versus host disease.
  • Another embodiment of the invention is directed to a process for preparing Form H pyridine solvate of ibrutinib, comprising exposing ibrutinib to pyridine to yield Form H pyridine solvate of ibrutinib.
  • Another embodiment of the invention is directed to a process for preparing Form I pyridine solvate of ibrutinib, comprising exposing ibrutinib to pyridine and water to yield Form I pyridine solvate of ibrutinib.
  • Techniques for characterizing crystal and amorphous forms include, but are not limited to differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), X-ray powder diffractometry (XRPD), proton nuclear magnetic resonance ( 1 H- MR) and Optical Microscopy.
  • DSC differential scanning calorimetry
  • TGA thermal gravimetric analysis
  • XRPD X-ray powder diffractometry
  • 1 H- MR proton nuclear magnetic resonance
  • Optical Microscopy Optical Microscopy.
  • DSC data are collected using a TA Instruments Q10 DSC. Approximately, samples (2-8 mg) are placed in unsealed but covered hermetic alodined aluminum sample pans and scanned from about 30 to about 300 °C at a rate of about 10 °C/min under a nitrogen purge of about 50 mL/min.
  • Modulated DSC data are collected using a TA Instruments Q2000 equipped with an auto-sampler and RSC40. Samples are equilibrated at 5 °C in Tzero hermetically sealed aluminum pans with a ramp rate of 1.5 °C/min to 200 °C under a nitrogen purge of about 50 mL/min, modulated ⁇ 0.50 °C every 60 seconds in T4P (or T4) mode.
  • TGA data are collected using a TA Instruments TGA Q500. Approximately, samples (5-10 mg) are placed in an open, pre-tared aluminum sample pan and scanned from about 25 to about 300 °C at a rate of about 10 °C/min using a nitrogen purge at about 60 mL/min.
  • the °2 ⁇ values and the relative intensity values are generated by performing a peak search on the measured data and the ⁇ i-spacing values are calculated by the instrument from the °2 ⁇ values using Bragg' s equation.
  • the relative intensity for the measured peaks may vary as a result of sample preparation, orientation and instrument used, for example.
  • TopSpin software Samples were prepared by dissolving the compound in deuterated methanol with 0.05% (v/v) tetramethylsilane (TMS). Spectra are collected at ambient temperature. The number of scans was at least 16 for 3 ⁇ 4-NMR.
  • Form H pyridine solvate of ibrutinib is a unique crystalline phase.
  • Form H pyridine solvate of ibrutinib is an off-white solid material.
  • the present disclosure provides processes for preparing Form H pyridine solvate of ibrutinib.
  • the process comprises exposing ibrutinib to a processing solvent.
  • the starting material in these processes may be produced by any suitable method, including synthesis known in the art.
  • the processing solvent may include ICH Q3 processing solvents, either alone or in combination, including water.
  • the processing solvent is pyridine.
  • Form I pyridine solvate of ibrutinib is a unique crystalline phase.
  • Form I is an off- white solid material.
  • the present disclosure provides processes for preparing Form I pyridine solvate of ibrutinib.
  • the process comprises exposing ibrutinib to a processing solvent and water.
  • the starting material in these processes may be produced by any suitable method, including synthesis known in the art.
  • the processing solvent may include ICH Q3 processing solvents, either alone or in combination.
  • the processing solvent is pyridine and water.
  • Amorphous ibrutinib is a white solid identified as amorphous by XRPD and has a glass transition (T g ) of approximately 55 °C.
  • T g glass transition
  • the amorphous ibrutinib described herein has a similar solubility to crystalline ibrutinib.
  • the present disclosure provides processes for preparing amorphous ibrutinib.
  • the process comprises the steps of dissolving ibrutinib in a solvent to form a solution, adding the solution to an anti-solvent and drying the resulting product to yield amorphous ibrutinib.
  • the starting material in these processes may be produced by any suitable method, including synthesis known in the art.
  • the solvent may be selected from the group comprising tetraglymes, polyethylene glycols, oligomeric ethylene glycols, oligomeric ethylene glycol monomethyl ethers, polyethylene glycol monomethyl ethers and pyridines.
  • Tetraglymes have the general formula Me(OCH2CH2)nOMe and may include diethylene glycol dimethyl ether (diglyme), triethylene glycol dimethyl ether
  • Suitable polyethylene glycols have the general formula H(OCH2CH2)nOH and have a molecular weight of 1000 or less.
  • polyethylene glycol may be selected from the group comprising PEG-200, PEG-400, and PEG-600, or a combination thereof.
  • Oligomeric ethylene glycols have the general formula H(OCH2CH2)nOH and may include ethylene glycol, diethylene glycol and triethylene glycol.
  • Oligomeric ethylene glycol monomethyl ethers and PEG monomethyl ethers have the general formula H(OCH2CH2)nOMe and may include methoxyethanol (ethylene glycol monomethyl ether, methyl cellusolve), diethylene glycol monomethyl ether, triethylene glycol monomethyl ether.
  • Pyridines may include pyridine,
  • methypyridines (picolines), dimethylpyridines (lutidines) and ethylpyridines.
  • compositions comprising Form H pyridine solvate of ibrutinib, Form I pyridine solvate of ibrutinib or amorphous ibrutinib.
  • Pharmaceutical compositions containing forms ibrutinib may be prepared according to International Publication Nos. WO2009/147238 and
  • the present disclosure provides for a method of treating disease by administering to a patient, in need thereof, pharmaceutical compositions comprising Form H pyridine solvate of ibrutinib, Form I pyridine solvate of ibrutinib or amorphous ibrutinib.
  • Ibrutinib is indicated for the treatment of patients with mantel cell lymphoma who have received at least one prior therapy.
  • Ibrutinib is also indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), CLL/SLL with 17p deletion, Waldenstrom's macroglobulinemia (WM), marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20- based therapy, and chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
  • CLL chronic lymphocytic leukemia
  • SLL small lymphocytic lymphoma
  • WM Waldenstrom's macroglobulinemia
  • MZL marginal zone lymphoma
  • cGVHD chronic graft versus host disease
  • the dosage of the pharmaceutical compositions may be varied over a wide range.
  • Optimal dosages and dosage regimens to be administered may be readily determined by those skilled in the art, and will vary with the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient's sex, age, weight, diet, physical activity, time of administration and concomitant diseases, will result in the need to adjust dosages and/or regimens.
  • Ibrutinib marketed under the name IMBRUVICA®, is available as 140 mg capsules. The recommended dose of ibrutinib in patients with mantle cell lymphoma or MZL is 560 mg (four 140 mg capsules), orally, once daily.
  • the recommended dose of ibrutinib in patients with chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia or CLL/SLL is 420 mg (three 140 mg capsules), orally, once daily.
  • the recommended dose in patients with cGVHD after failure of one or more lines of systemic therapy is 420 mg (three 140 mg capsules), orally, once daily
  • Examples 1-5 which follow herein, provide embodiments of the preparation of solid state forms of ibrutinib.
  • Form H pyridine solvate of ibrutinib About 250 mg of ibrutinib is dissolved in about 375 ⁇ _, of pyridine under ambient temperature conditions. The solution is stirred at about 5 °C overnight. The isolated, wet product is analyzed by XRPD and identified as Form H pyridine solvate of ibrutinib. The dried product is also analyzed and identified as Form H pyridine solvate of ibrutinib.
  • ibrutinib About 57 mg of ibrutinib is dissolved in about 900 ⁇ _, of tetraglyme. The solution is slowly added dropwise into about 15 mL of cold water. The resulting material is allowed to stir for approximately 90 minutes and isolated by filtration. The isolated, wet product is analyzed by XRPD and identified as amorphous ibrutinib. The product is dried under vacuum at about 45 °C. The dried product is analyzed and identified as amorphous ibrutinib. Representative XRPD pattern, modulated DSC plot, and 1 H- MR plot of amorphous ibrutinib prepared using tetraglyme, are shown respectively in Fig. 3-5. Example 3
  • the DSC thermogram of the amorphous ibrutinib, FIG. 10, shows an average thermal event at about 54.9 °C.
  • the amorphous ibrutinib described herein is characterized by a glass transition (T g ) of approximately 55 °C.
  • ibrutinib is dissolved in 1 mL of pyridine. A few drops (4-5) of water are added to the vial with a transfer pipette. The vial is placed in a hood
  • Figure 14 shows the asymmetric unit of Form I pyridine solvate of ibrutinib.
  • Figure 15 shows the inter and intra molecular hydrogen bonding between ibrutinib and pyridine molecules in Form I pyridine solvate of ibrutinib.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes d'ibrutinib, à savoir, un solvate de pyridine de forme cristalline H de la forme H d'ibrutinib, un solvate de pyridine de forme cristalline I d'ibrutinib et une forme amorphe d'ibrutinib. La présente invention concerne également une composition pharmaceutique comprenant les formes, un procédé d'utilisation des formes pour traiter une maladie chez un patient, et un procédé pour la préparation des formes.
PCT/US2018/053954 2017-10-02 2018-10-02 Nouvelles formes d'ibrutinib Ceased WO2019070698A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566767P 2017-10-02 2017-10-02
US62/566,767 2017-10-02

Publications (1)

Publication Number Publication Date
WO2019070698A1 true WO2019070698A1 (fr) 2019-04-11

Family

ID=63963531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/053954 Ceased WO2019070698A1 (fr) 2017-10-02 2018-10-02 Nouvelles formes d'ibrutinib

Country Status (1)

Country Link
WO (1) WO2019070698A1 (fr)

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147238A1 (fr) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques solides comprenant du bibw 2992
WO2011003853A2 (fr) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Procédé de séchage du bibw2992, de ses sels et des préparations pharmaceutiques solides contenant ce principe actif
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
CN103923084A (zh) 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
US20140336203A1 (en) 2012-06-04 2014-11-13 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2016079216A1 (fr) * 2014-11-20 2016-05-26 Sandoz Ag Formes physiques de l'ibrutinib, un inhibiteur de la kinase de bruton
CN105622614A (zh) * 2015-12-18 2016-06-01 重庆医药工业研究院有限责任公司 一种依鲁替尼无定型物及其制备方法
WO2016088074A1 (fr) 2014-12-03 2016-06-09 Dr. Reddy’S Laboratories Limited Procédé pour la préparation d'ibrutinib amorphe
WO2016207172A1 (fr) 2015-06-26 2016-12-29 Sandoz Gmbh Préparation d'ibrutinib amorphe pur
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
WO2017029586A1 (fr) 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Formes cristallines d'ibrutinib
WO2017074265A1 (fr) * 2015-10-28 2017-05-04 Scinopharm Taiwan, Ltd. Procédé de préparation d'ibrutinib et de ses intermédiaires
WO2017085628A1 (fr) 2015-11-16 2017-05-26 Olon S.P.A. Procédé de préparation de la forme amorphe d'ibrutinib et d'une nouvelle forme cristalline associée
WO2017137446A1 (fr) 2016-02-09 2017-08-17 Azad Pharmaceutical Ingredients Ag Procédé de synthèse d'ibrutinib amorphe stable
US9751889B2 (en) 2013-11-27 2017-09-05 Crystal Pharmatech Inc. Crystalline form I of ibrutinib
WO2017174044A1 (fr) 2016-04-06 2017-10-12 Zentiva, K.S. Formes solides d'ibrutinib
EP3243824A1 (fr) 2016-05-11 2017-11-15 Zentiva K.S. Les formes solides de la base libre de l'ibrutinib
WO2018000250A1 (fr) 2016-06-29 2018-01-04 上海创诺医药集团有限公司 Nouvelle forme cristalline ibrutinib et méthode de préparation de celle-ci
US9884869B2 (en) 2014-03-27 2018-02-06 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
US20180051026A1 (en) 2015-03-03 2018-02-22 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
US20180065958A1 (en) 2015-03-20 2018-03-08 Crystal Pharmatech Co., Ltd Preparation method of pci-32765 crystal form a
US20180072739A1 (en) 2015-03-27 2018-03-15 Pharmacyclic LLC Co-crystals of a bruton's tyrosine kinase inhibitor
US20180072737A1 (en) 2015-04-02 2018-03-15 Ratiopharm Gmbh Co-crystals of ibrutinib with carboxylic acids
US9972545B2 (en) 2015-10-30 2018-05-15 Taiwan Semiconductor Manufacturing Company, Ltd. System and method for a field-effect transistor with dual vertical gates
US10035802B2 (en) 2014-08-14 2018-07-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ibrutinib

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147238A1 (fr) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques solides comprenant du bibw 2992
WO2011003853A2 (fr) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Procédé de séchage du bibw2992, de ses sels et des préparations pharmaceutiques solides contenant ce principe actif
US20140336203A1 (en) 2012-06-04 2014-11-13 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US9828383B1 (en) 2012-06-04 2017-11-28 Pharmacyclic s LLC Crystalline forms of a bruton's tyrosine kinase inhibitor
US20170305919A1 (en) 2012-06-04 2017-10-26 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9751889B2 (en) 2013-11-27 2017-09-05 Crystal Pharmatech Inc. Crystalline form I of ibrutinib
CN103923084A (zh) 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
US20180251463A1 (en) 2014-03-27 2018-09-06 Wavelength Enterprises Ltd. Ibrutinib solid forms and production process therefor
US9884869B2 (en) 2014-03-27 2018-02-06 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
US20170079981A1 (en) 2014-08-07 2017-03-23 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
US20180028537A1 (en) 2014-08-07 2018-02-01 Pharmacyclics Llc Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
US10035802B2 (en) 2014-08-14 2018-07-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ibrutinib
WO2016079216A1 (fr) * 2014-11-20 2016-05-26 Sandoz Ag Formes physiques de l'ibrutinib, un inhibiteur de la kinase de bruton
WO2016088074A1 (fr) 2014-12-03 2016-06-09 Dr. Reddy’S Laboratories Limited Procédé pour la préparation d'ibrutinib amorphe
US20180051026A1 (en) 2015-03-03 2018-02-22 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
US20180065958A1 (en) 2015-03-20 2018-03-08 Crystal Pharmatech Co., Ltd Preparation method of pci-32765 crystal form a
US20180072739A1 (en) 2015-03-27 2018-03-15 Pharmacyclic LLC Co-crystals of a bruton's tyrosine kinase inhibitor
US20180072737A1 (en) 2015-04-02 2018-03-15 Ratiopharm Gmbh Co-crystals of ibrutinib with carboxylic acids
WO2016207172A1 (fr) 2015-06-26 2016-12-29 Sandoz Gmbh Préparation d'ibrutinib amorphe pur
WO2017029586A1 (fr) 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Formes cristallines d'ibrutinib
WO2017074265A1 (fr) * 2015-10-28 2017-05-04 Scinopharm Taiwan, Ltd. Procédé de préparation d'ibrutinib et de ses intermédiaires
US9972545B2 (en) 2015-10-30 2018-05-15 Taiwan Semiconductor Manufacturing Company, Ltd. System and method for a field-effect transistor with dual vertical gates
WO2017085628A1 (fr) 2015-11-16 2017-05-26 Olon S.P.A. Procédé de préparation de la forme amorphe d'ibrutinib et d'une nouvelle forme cristalline associée
CN105622614A (zh) * 2015-12-18 2016-06-01 重庆医药工业研究院有限责任公司 一种依鲁替尼无定型物及其制备方法
WO2017137446A1 (fr) 2016-02-09 2017-08-17 Azad Pharmaceutical Ingredients Ag Procédé de synthèse d'ibrutinib amorphe stable
WO2017174044A1 (fr) 2016-04-06 2017-10-12 Zentiva, K.S. Formes solides d'ibrutinib
EP3243824A1 (fr) 2016-05-11 2017-11-15 Zentiva K.S. Les formes solides de la base libre de l'ibrutinib
WO2018000250A1 (fr) 2016-06-29 2018-01-04 上海创诺医药集团有限公司 Nouvelle forme cristalline ibrutinib et méthode de préparation de celle-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"The United States Pharmacopeia", 1995, pages: 1843 - 1844
REMINGTON: "The Science and Practice of Pharmacy", 2005, IPPINCOTT, WILLIAMS AND WILKINS

Similar Documents

Publication Publication Date Title
EP2603503B1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
JP2021530456A (ja) ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態
US20230374030A1 (en) Solid-state forms of relugolix
US20210221787A1 (en) Niraparib solid state form
US12030886B2 (en) Form of ponatinib
AU2019379797B2 (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
EP2551257A1 (fr) Co-cristaux d'agomélatine avec formeurs de co-cristaux
US20220251091A1 (en) Amorphous umbralisib monotosylate
US11306062B2 (en) Forms of fedratinib dihydrochloride
WO2019070698A1 (fr) Nouvelles formes d'ibrutinib
US11440908B2 (en) Crystalline forms of dasatinib
CN107522695B (zh) 一种pim激酶抑制剂的盐酸盐及其制备方法和用途
US11066401B2 (en) Pyrimidine compound, chloride salt thereof, and manufacturing and application of same
WO2020072870A1 (fr) Formes co-cristallines du baricitinib
US11136314B2 (en) Forms of afatinib dimaleate
JP7711900B2 (ja) ヌクレオシド類似体の塩及びその結晶形、医薬組成物並びに用途
WO2019195827A1 (fr) Nouvelle forme d'ibrutinib
US20230159468A1 (en) Novel forms of pracinostat dihydrochloride
US20210395232A1 (en) Co-crystal forms of selinexor
EP3184516A1 (fr) Complexe d'inclusion crystallin de mirabegron avec beta-cyclodextrine
WO2024157139A1 (fr) Formes polymorphes de savolitinib
US20210246159A1 (en) Novel form of bardoxolone methyl
KR20250026776A (ko) 고요산혈증 또는 통풍 치료 또는 예방을 위한 화합물의 고체 결정형

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18792737

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18792737

Country of ref document: EP

Kind code of ref document: A1